共 50 条
- [21] Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (12) : 2166 - +Haddad, Robert I.Harrington, KevinTahara, MakotoFerris, Robert L.Gillison, MauraFayette, JeromeDaste, AmauryKoralewski, PiotrZurawski, BogdanTaberna, MirenSaba, Nabil F.Mak, MilenaKawecki, AndrzejGirotto, GustavoAlvarez Avitia, Miguel AngelEven, CarolineToledo, Joaquin Gabriel ReinosoGuminski, AlexanderMuller-Richter, UrsKiyota, NaomiRoberts, MustimboKhan, Tariq AzizMiller-Moslin, KarenWei, LiArgiris, Athanassios
- [22] Cetuximab plus folfiri first-line in metastatic colorectal cancer (MCRC): The randomized phase III crystal trialANNALS OF ONCOLOGY, 2007, 18 : VII21 - VII21Koehne, C.Zaluski, J.Chung, Rong C.Makhson, A.D'Haens, G.Pinter, T.Lim, R.Ruff, P.Rougier, P.Van Cutsem, E.
- [23] Nivolumab plus cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trialANNALS OF ONCOLOGY, 2020, 31 : S1159 - S1159Choueiri, T. K.Powles, T.Burotto, M.Bourlon, M. T.Zurawski, B.Oyervides Juarez, V. M.Hsieh, J. J.Basso, U.Shah, A. Y.Suarez, C.Hamzaj, A.Barrios, C. H.Richardet, M.Pook, D.Tomita, Y.Escudier, B.Zhang, J.Simsek, B.Apolo, A. B.Motzer, R. J.
- [24] Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trialNature Medicine, 2021, 27 : 1536 - 1543Hai-Qiang MaiQiu-Yan ChenDongping ChenChaosu HuKunyu YangJiyu WenJingao LiYing-Rui ShiFeng JinRuilian XuJianji PanShenhong QuPing LiChunhong HuYi-Chun LiuYi JiangXia HeHung-Ming WangWan-Teck LimWangjun LiaoXiaohui HeXiaozhong ChenZhigang LiuXianglin YuanQi LiXiaoyan LinShanghua JingYanju ChenYin LuChing-Yun HsiehMuh-Hwa YangChia-Jui YenJens SamolHui FengSheng YaoPatricia KeeganRui-Hua Xu
- [25] Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trialNATURE MEDICINE, 2021, 27 (09) : 1536 - +Mai, Hai-QiangChen, Qiu-YanChen, DongpingHu, ChaosuYang, KunyuWen, JiyuLi, JingaoShi, Ying-RuiJin, FengXu, RuilianPan, JianjiQu, ShenhongLi, PingHu, ChunhongLiu, Yi-ChunJiang, YiHe, XiaWang, Hung-MingLim, Wan-TeckLiao, WangjunHe, XiaohuiChen, XiaozhongLiu, ZhigangYuan, XianglinLi, QiLin, XiaoyanJing, ShanghuaChen, YanjuLu, YinHsieh, Ching-YunYang, Muh-HwaYen, Chia-JuiSamol, JensFeng, HuiYao, ShengKeegan, PatriciaXu, Rui-Hua
- [26] A Phase 3 Trial of Nivolumab, Nivolumab Plus Ipilimumab, or Placebo Maintenance for Extensive-Stage SCLC After First-Line ChemotherapyJOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S306 - S307Owonikoko, TaofeekReady, NealPostmus, PieterReck, MartinPeters, SolangePieters, AnneSelvaggi, GiovanniFairchild, JustinGovindan, Ramaswamy
- [28] Phase III trial evaluating paclitaxel plus carboplatin versus paclitaxel plus epirubicin as first-line treatment for metastatic breast cancerCANCER RESEARCH, 2015, 75Tong, ZhongshengLi, ShufenShi, YehuiWang, XuHao, ChunfangHe, LihongDong, GuoleiWang, XiaoruiJia, YongshengZhang, Li
- [29] Checkmate 743: A phase 3 randomized, open-label trial of nivolumab (nivo) plus ipilimumab (ipi) vs pemetrexed plus cisplatin or carboplatin as first-line therapy in unresectable pleural mesothelioma.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Zalcman, GerardPeters, SolangeMansfield, Aaron ScottJahan, Thierry MariePopat, SanjayScherpereel, ArnaudHu, WenhuaSelvaggi, GiovanniBaas, Paul
- [30] Paclitaxel plus carboplatin versus paclitaxel plus epirubicin as first-line treatment for metastatic breast cancer: Efficacy and safety results of a randomized, phase III trial.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Tong, ZhongshengLi, ShufenShi, YehuiWang, XuWang, ChenHao, ChunfangWang, XiaoruiMeng, WenjinZhang, Li